ASH24 Social Influencer Conversations in Full Swing

ASH24 Pre-Conference Collaboration Is In Full Swing

Check out this social network diagram generated based on the ASH24 conversations ahead of the conference.  This content was generated in minutes using KOL Pulse AI technology and is completely interactive.  Hover over the nodes to see the KOL and follow their network.  Zoom in and out to see the detail.  Drag nodes to organize networks based on KOL.  Larger nodes show who's been most prolific on X.  The connections show retweets and mentions.   See down below for the top conversations being followed.

If you find this interesting and want access to the same tools I used to create this summary in minutes, contact us for a demo.

Top Trending Conversations for ASH24

1. Aaron Goodman (@AaronGoodman33):
- Highlighted key abstract on high risk smoldering myeloma, including data showing majority don't progress at 3 years [Source](https://hubs.ly/Q02-LF6y0)
- Criticized use of CAR-T in smoldering myeloma studies [Source](https://hubs.ly/Q02-LKJy0)
- Shared analysis of POLARIX 5-year follow-up data for DLBCL [Source](https://hubs.ly/Q02-Lt1p0)

2. Samer Al Hadidi (@HadidiSamer):
- Provided a comprehensive top 10 ASH24 abstracts for plasma cell disorders/multiple myeloma [Source](https://hubs.ly/Q02-LBv20)
- Highlighted ANDROMEDA overall survival results [Source](https://hubs.ly/Q02-LLf60)
- Discussed PANGEA-2 model for predicting smoldering myeloma progression [Source](https://hubs.ly/Q02-LCwr0)

3. Rahul Banerjee (@RahulBanerjeeMD):
- Shared detailed analysis of top 10 myeloma abstracts focusing on response assessments, optimizing bispecific antibodies, and practice-changing studies [Source](https://hubs.ly/Q02-LBlK0)
- Highlighted urine-free IMWG response criteria study [Source](https://hubs.ly/Q02-LB2X0)
- Discussed AQUILA trial of daratumumab in high-risk smoldering myeloma [Source](https://hubs.ly/Q02-LB2p0)

4. Muzaffar Qazilbash (@Transplant_Doc):
- Shared insights on impact of previous HDM/ASCT on PFS with BCMA-directed CAR-T therapy [Source](https://hubs.ly/Q02-LC6_0)
- Highlighted study on 24-hour urine testing in myeloma response assessments [Source](https://hubs.ly/Q02-LtNh0)
- Discussed MRD analysis from Phase III Cepheus Trial [Source](https://hubs.ly/Q02-LB1d0)

5. Ben Derman (@bdermanmd):
- Highlighted key abstracts on Dara-R vs Rd in frail patients, Talquetamab bridging before BCMA CAR T, and Anito-cel Phase 2 results [Source](https://hubs.ly/Q02-LB4N0)

6. Raj Chakraborty (@rajshekharucms):
- Provided insights on multiple studies including MASTER trial, GMMG-HD7, DREAMM7, AQUILA trial, and IFM 2017-03 trial [Source](https://hubs.ly/Q02-Lz5d0)

7. Mike Thompson (@mtmdphd):
- Shared a comprehensive list of important abstracts covering NDMM, RRMM, and basic/translational research [Source](https://hubs.ly/Q02-LB7N0)

8. Saad Z. Usmani (@szusmani):
- Compiled a "best of ASH24" abstract list covering clinical and basic/translational research in NDMM and RRMM [Source](https://hubs.ly/Q02-Lt9J0)